Biotech | November 23, 2021
AstraZeneca opens Discovery Centre in Cambridge
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Subscribe To Our Newsletter & Stay Updated
